Login
Search
Search
0 Dates
2026
2025
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
CPC 2025
CPC 2026
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Beyond Pulmonary Pressure: HFA-PEFF Reveals Hidden Risk in CTEPH
Session:
Sessão de Posters 27 - Abordagem e avanços terapêuticos na hipertensão pulmonar
Speaker:
Sofia Esteves
Congress:
CPC 2026
Topic:
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
Theme:
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
Subtheme:
21.2 Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure – Epidemiology, Prognosis, Outcome
Session Type:
Posters Eletrónicos
FP Number:
---
Authors:
Sofia Esteves; Diogo Ferreira; Daniel Inácio Cazeiro; Marta Vilela; Inês Araújo; Beatriz Andrade; Rita Figueiredo; João Reis Sabido; Manuel Abecasis; Ricardo Ferreira; Tatiana Guimarães; Rui Plácido
Abstract
<p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Aptos,sans-serif"><strong><span style="font-family:"Calibri",sans-serif">Introduction: </span></strong><span style="font-family:"Calibri",sans-serif">Chronic thromboembolic pulmonary hypertension (CTEPH) is a severe form of pulmonary hypertension with persistently high morbidity and mortality. Risk stratification usually relies on right-sided hemodynamics and functional status. Many patients have comorbidities that affect prognosis. The HFA-PEFF score, created to diagnose and stratify heart failure with preserved ejection fraction (HFpEF), integrates structural, functional and biomarker domains. Whether this multidimensional tool adds prognostic value in CTEPH is unknown. We aimed to evaluate the prognostic relevance of the HFA-PEFF score in a well-phenotyped cohort of confirmed CTEPH patients.</span></span></span></p> <p style="text-align:justify"> </p> <p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Aptos,sans-serif"><strong><span style="font-family:"Calibri",sans-serif">Methods: </span></strong><span style="font-family:"Calibri",sans-serif">This study included patients with CTEPH diagnosed and followed at a tertiary PH centre between December 2013 and May 2024. Patients were stratified into low, intermediate, or high-risk of HFpEF according to the HFA-PEFF score. The primary endpoint was the composite of all-cause mortality and hospitalizations for any cause. Clinical, biochemical, imaging and hemodynamic variables were extracted from baseline assessment.</span></span></span></p> <p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:"Times New Roman",serif"><strong><span style="font-family:"Calibri",sans-serif">Results: </span></strong><span style="font-family:"Calibri",sans-serif">A total of 54 patients (64.8% female) with a mean age of 66.2 years were included. The most frequent comorbidities included obstructive sleep apnea (20.4%) and pulmonary disease (25.9%). At baseline, the median NT-proBNP was 963.5?pg/mL [IQR 3738]; Echocardiography, pulmonary function tests and hemodynamic parameters are at <u>Table 1.</u> Most patients received targeted therapy (74.1%) and 35% underwent pulmonary endarterectomy. Regarding the functional status at baseline, the mean 6-minute walking distance was 264.6?±?117.5 meters and 84% of the patients were in OMS class II–III. Based on the HFA-PEFF score, 7.4% of patients were had low risk of HFpEF, 61.1% had intermediate risk and 31.5% had high risk. After a median follow up of 12 months, the primary endpoint occurred in 33 patients (61.1%)- 27 hospitalizations and 6 deaths. Stratification according to HFpEF score showed that high-risk group experienced a higher incidence of events over time, while those in the low-risk group had a lower incidence. The difference between the groups was statistically significant (log-rank p = 0.041), indicating that the HFA-PEFF score effectively stratifies patients’ risk of events- <u>Graph1</u> .</span></span></span></p> <p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Aptos,sans-serif"><strong><span style="font-family:"Calibri",sans-serif">Conclusions:</span></strong><span style="font-family:"Calibri",sans-serif"> In this real-world CTEPH cohort, higher HFA-PEFF scores were strongly linked to greater hospitalization and mortality risk. These results indicate that the score reflects not only coexisting HFpEF but also serves as a prognostic marker in CTEPH. The algorithm appears to identify a vulnerable CTEPH–HFpEF phenotype with a clearly worse trajectory. Incorporating HFA-PEFF into baseline assessment may enhance risk stratification and support more individualized therapy.</span></span></span></p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site